MindWalk Holdings (HYFT) Asset Writedowns and Impairment (2020 - 2024)
MindWalk Holdings (HYFT) posted quarterly Asset Writedowns and Impairment of $11.1 million for Q2 2024, up 237526.59% quarter-over-quarter from $4665.2 in Q3 2022.
Analysis
MindWalk Holdings (HYFT) Asset Writedowns and Impairment (2020 - 2024) Analysis & Trends
MindWalk Holdings (HYFT) has reported Asset Writedowns and Impairment for 4 consecutive years, with $11.1 million the latest figure, recorded in Q2 2024.
- In Q2 2024, Asset Writedowns and Impairment changed N/A year-over-year to $11.1 million; the TTM figure through Apr 2024 stood at $11.2 million (changed N/A YoY), while the FY2024 annual figure was $11.1 million, up 512.58% from the prior year.
- Asset Writedowns and Impairment improved to $11.1 million in Q2 2024 per HYFT's latest filing, from $4665.2 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $11.1 million in Q2 2024 and bottomed at -$34307.3 in Q2 2021.
- Historically, Asset Writedowns and Impairment has averaged $1.2 million across 4 years, with a median of -$16.7 in 2021.
- Annual changes were most pronounced in 2021 — Asset Writedowns and Impairment surged 99.86% — and 2022, when it jumped 557.4%.
- MindWalk Holdings' Asset Writedowns and Impairment stood at -$12101.3 in 2020, then soared by 99.86% to -$16.7 in 2021, then surged by 28028.09% to $4665.2 in 2022, then jumped by 237526.59% to $11.1 million in 2024.
- Business Quant data shows HYFT's Asset Writedowns and Impairment at $11.1 million in Q2 2024, $4665.2 in Q3 2022, and $127135.0 in Q2 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | MindWalk Holdings | 60.76 Mn | 52.48 Mn | 1.82 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2024 | 11.09 Mn |
| Oct 31, 2021 | -16,704.19 |
| Jan 31, 2021 | 8,506.01 |
| Oct 31, 2020 | 24,390.87 |